VYDAPTIV
Dead / Abandoned — Abandoned — no statement of use filed (as of 29 May 2023)
What this means for you
This application is over — abandoned 29 May 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88664224
- Mark type
- Stylized text
- Filed
- 22 Oct 2019
- Published for opposition
- 03 Mar 2020
- Abandoned
- 29 May 2023
- Attorney of record
- Monica Riva Talley
Goods and services
- Class 001 — Chemicals: Therapeutic protein molecules used in the manufacture of pharmaceutics and biologically-derived medical preparations; all the foregoing to exclude such molecules relating to antibiotics and pharmaceutical preparations for the treatment and prophylaxis of infectious diseases
- Class 005 — Pharmaceuticals: Pharmaceutical preparations containing polypeptides, antibodies, or antibody derivatives for the treatment and prophylaxis of cancer and immune system diseases and disorders, and autoimmune system diseases, namely, neurological and neuromuscular diseases and disorders, gastrointestinal diseases, nervous system diseases and disorders, respiratory system diseases, lymphatic system diseases, primary and secondary immunodeficiency disorders, genetic autoimmune diseases, severe combined immunodeficiency diseases, immune complex diseases, and immunodeficiency diseases, including, allergies, asthma, diabetes, rheumatoid arthritis, multiple sclerosis, lupus, Hashimoto's, inflammatory bowel disease, Guillain-Barre, psoriasis, chronic inflammatory demyelinating polyneuropathy (CIPD), Graves' disease, myasthenia gravis, and transplant rejection diseases, and blood disorders, all of the foregoing to exclude antibiotics and pharmaceutical preparations for the treatment and prophylaxis of infectious diseases
- Class 042 — Scientific and technological services: Research and development in the pharmaceutical and biotechnology fields relating to polypeptides, antibodies or antibody derivatives, in relation to the treatment and prophylaxis of cancer, immune system diseases and disorders, and autoimmune system diseases, namely, neurological and neuromuscular diseases and disorders, gastrointestinal diseases, nervous system diseases and disorders, respiratory system diseases, lymphatic system diseases, primary and secondary immunodeficiency disorders, genetic autoimmune diseases, severe combined immunodeficiency diseases, immune complex diseases, and immunodeficiency diseases, including, allergies, asthma, diabetes, rheumatoid arthritis, multiple sclerosis, lupus, Hashimoto's, inflammatory bowel disease, Guillain-Barre, psoriasis, chronic inflammatory demyelinating polyneuropathy (CIPD), Graves' disease, myasthenia gravis, and transplant rejection diseases, and blood disorders, all of the foregoing to exclude research and development in relation to antibiotics and the treatment and prophylaxis of infectious diseases
Owner
- Aptevo Therapeutics, Inc., Seattle, WA, US
- Aptevo Therapeutics, Inc., Seattle, WA, US
Prosecution history
- 30 May 2023 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 29 May 2023 — ABANDONMENT - NO USE STATEMENT FILED
- 08 Nov 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Nov 2022 — SOU EXTENSION 5 GRANTED
- 28 Oct 2022 — SOU EXTENSION 5 FILED
- 07 Nov 2022 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 28 Oct 2022 — SOU TEAS EXTENSION RECEIVED
- 30 Apr 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 28 Apr 2022 — SOU EXTENSION 4 GRANTED
- 28 Apr 2022 — SOU EXTENSION 4 FILED
- 28 Apr 2022 — SOU TEAS EXTENSION RECEIVED
- 30 Oct 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 28 Oct 2021 — SOU EXTENSION 3 GRANTED
- 28 Oct 2021 — SOU EXTENSION 3 FILED
- 28 Oct 2021 — SOU TEAS EXTENSION RECEIVED